RBC Capital reiterated coverage on Aurinia Pharmaceuticals with a new price target

2/23/22 9:29:09 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

RBC Capital reiterated coverage of Aurinia Pharmaceuticals with a rating of Outperform and set a new price target of $31.00 from $34.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AUPH

Date	Price Target	Rating	Analyst
11/4/2022		Outperform → Perform	Oppenheimer
5/5/2022	$34.00 → $25.00	Overweight	Cantor Fitzgerald
3/8/2022	$30.00 → $22.00	Outperform	SVB Leerink
3/1/2022	$31.00 → $27.00	Outperform	RBC Capital
2/23/2022	$34.00 → $31.00	Outperform	RBC Capital
12/10/2021	$33.00 → $31.00	Perform → Outperform	Oppenheimer
11/4/2021	$32.00 → $33.00	Perform	Oppenheimer
11/4/2021	$35.00 → $40.00	Buy	HC Wainwright & Co.